Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.


Project Scope

The scope of this project is to evaluate and recommend approaches for SEND harmonization to better enable analysis of historical control data. SEND harmonization strategies include creation of new variables, controlled terminology, preferred terms, reference lists and/or analysis strategies (scripts) to enable cross study analysis. Developing a solution framework for variability that includes representation of stakeholders involved in the creation and use of SEND datasets will enable more efficient routine analysis of warehoused SEND data.



Project Leads

Email

Kevin Snyder (FDA)

kevin.snyder@fda.hhs.gov

Mark Carfagna (Eli Lilly)

carfagna_mark_a@lilly.com

Alex Pearce (PHUSE Project CoordinatorAssistant

Alexandra@phuse.global

Objectives & DeliverablesTimelines


Develop plans for a new, re-scoped project that will focus exclusively on applying harmonisation of SEND data to facilitate implementation of virtual control groups in toxicology studies.Q2 2023

Status
colourBlue
titleCurrent Status
Q2 2023

  • Project Successfully kicked-off 
  • Working document templates agreed




Objectives & DeliverablesTimelines
Develop plans for a new, re-scoped project that will focus exclusively on applying harmonisation of SEND data to facilitate implementation of virtual control groups in toxicology studies.Q2 2023

Project Members 

Organisation Annika KreuchwigBayerBill HouserBristol Myers Squibb,  BioCelerate ConsortiumCara Rinaldi BioCelerate

Cheryl Sloan

Bristol Myers Squibb,  BioCelerate Consortium

Deepa Smant

ComcastFrank BringezuMerck 

Gen Sato

Eisai Joseph Horvath Bristol Myers SquibbLaura Kaufman PointcrossLokesh Babu PointcrossMichael DeNieu LabcorpMichael WaskoPDS Life Sciences 

Michele Dunleavy

BiocelerateNicolas PhilippePointCross Life Sciences Patricia BrundageFDARick ThompsonJanssen Research & Development,  BioCelerate Consortium

Rupesk Katta

XybionSivaRamaKrishna VemiReddy PointcrossSteve PolleyGSK

Sudharrshan Muthukumarasamy

XybionSue DehavenSanofiTodd PageEli LillyVidhuna SadanandanLabcorpWang WenxianBristol Myers Squibb,  BioCelerate ConsortiumWilliam Houser Bristol Myers Squibb